Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Others

Ratios

Immunovant (IMVT) Asset Writedowns and Impairment (2019)

Immunovant filings provide 1 years of Asset Writedowns and Impairment readings, the most recent being $230000.0 for Q4 2019.

Quarterly Asset Writedowns and Impairment changed N/A to $230000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $230000.0 through Mar 2021, changed N/A year-over-year, with the annual reading at $1.6 million for FY2020, N/A changed from the prior year.
Asset Writedowns and Impairment hit $230000.0 in Q4 2019 for Immunovant.
Across five years, Asset Writedowns and Impairment topped out at $230000.0 in Q4 2019 and bottomed at $230000.0 in Q4 2019.